Mean (95% CI) change in secondary outcomes: CRQ domains, symptoms and sputum characteristics after mometasone compared with placebo for each tertile
| Eosinophil count | |||||
|---|---|---|---|---|---|
| <1 (n = 20) | 1–3.9 (n = 20) | >3.9 (n = 20) | |||
| CRQ, Chronic Respiratory Disease Questionnaire; SOB, shortness of breath; VAS, visual analogue score; TCC, total cell count; IL-8, interleukin 8; ECP, eosinophilic cationic protein. | |||||
| *p<0.05. | |||||
| †Fold decrease; ‡absolute increase, ¶absolute decrease (mm). | |||||
| CRQ domains‡ | |||||
| SOB | −0.31 (−0.9 to 0.3) | −0.2 (−0.9 to 0.5) | 0.35 (−0.3 to 1.0) | ||
| Fatigue | −0.16 (−0.67 to 0.35) | −0.19 (−1.05 to 0.67) | 0.15 (−0.41 to 0.71) | ||
| Emotion | −0.23 (−0.63 to 0.17) | −0.44 (−0.89 to 0.003) | −0.09 (−0.69 to 0.51) | ||
| Mastery | −0.32 (−0.79 to 0.13) | −0.08 (−0.78 to 0.60) | 0.31 (−0.40 to 1.02) | ||
| Symptom scores (VAS)¶ | |||||
| Cough | 2 (−8 to 13) | 10 (−1 to 21) | 3 (−3 to 8) | ||
| Sputum | −15 (−30 to 0) | 3 (−8 to 14) | −5 (−17 to 7) | ||
| SOB | −12 (−30 to 7) | 5 (−4 to 13) | −3 (−16 to 10) | ||
| Wheeze | −8 (−17 to 2) | 3 (−4 to 10) | −7 (−17 to 4) | ||
| Sputum indices | |||||
| TCC‡ | −0.3 (−3.2 to 2.7) | 1.9 (−5.7 to 9.4) | 0.1 (−1.7 to 2.0) | ||
| Eosinophils† | 0.44 (0.27 to 0.73)* | 0.9 (0.42 to 1.96) | 1.37 (0.74 to 2.54) | ||
| Neutrophils‡ | −7.9 (−23 to 8) | 2.3 (−7 to 12) | −7.2 (−18 to 4) | ||
| Histamine (ng/g)† | 1.1 (0.5 to 1.4) | 0.8 (0.5 to 1.2) | 0.9 (0.7 to 1.1) | ||
| IL-8 (ng/g)† | 1.2 (0.9 to 1.6) | 1 (0.7 to 1.5) | 1.3 (0.9 to 1.8) | ||
| ECP (ng/g)† | 1.2 (0.96 to 1.5) | 0.9 (0.58 to 1.48) | 1.15 (0.9 to 1.45) | ||